Norvasc Patent Still Invalid: Court

Law360, New York (May 21, 2007, 12:00 AM EDT) -- An appeals court refused Monday to rehear Pfizer Inc.’s case against Apotex Inc., giving the Canadian generics-maker the green light to launch a generic form of Pfizer’s blockbuster blood-pressure drug Norvasc.

The U.S. Court of Appeals for the Federal Circuit denied Pfizer’s request for an en banc rehearing and left intact its previous ruling that found the pharmaceutical behemoth’s patent for Norvasc unenforceable. In so doing, the court granted Apotex’ request that it expedite its issuance of the decision.

The court’s previous ruling, handed down March...
To view the full article, register now.